In another clinical study, treatment of a small cohort of FXS patients with Lithium—which mitigates signaling pathways activated via mGluR5 signaling—resulted in significant behavioral improvements such in hyperactivity and inappropriate speech, however induced only a tendency for improvement in irritability, lethargy and repetitive behaviors [101]. Here, GRM5 is linked to fragile X syndrome.